Literature DB >> 21543108

New recommendations for thromboelastography reference ranges for pregnant women.

Ferdinand Polak1, Ivana Kolnikova, Michal Lips, Antonin Parizek, Jan Blaha, Martin Stritesky.   

Abstract

INTRODUCTION: The target of this study was to compare thromboelastography coagulation parameters in pregnant and non-pregnant women. If appropriate, we would propose recommendations for new reference ranges for pregnant women in their third trimester.
MATERIALS AND METHODS: Prospective observational study, comparing, by using thromboelastography, the blood samples of 60 healthy women in third trimester of pregnancy (group GRAV) to the samples of the control group of 43 healthy non-pregnant fertile women (group NON-GRAV). Selective percentiles were used to determine new reference limits.
RESULTS: Mean values and standard deviations (SD) in both groups were as follows (GRAV vs NON-GRAV): time r 4.7 min (SD 1.7) vs. 7.8 (SD 2.8); time k1.5 min (SD 0.5) vs. 2,7 (SD 0,9); alpha angle 69.6° (SD 5.5) vs. 54.4 (SD 11.5); maximum amplitude 71.3mm (SD 4.5) vs. 63.1 (SD 5.4); coagulation index 2.7 (SD 1.8) vs. -1.9 (SD 3.0); LY60 1.1% (SD 1.8) vs. 4.8 (SD 3.6). Due to statistically significant differences between both groups, we established, based on our results, these new thromboelastography reference limits for pregnant women: time r 2-8 min ("common" range 4-8 min), time k 1-3 min ("common" range 1-4 min), alpha angle 60-77° ("common" range 47-74°), maximum amplitude 64-76 mm ("common" range 55-73 mm), LY60 0-3% ("common" range 0-15%), coagulation index 0-5 ("common" range (-3) - (+3)).
CONCLUSIONS: It may not be suitable to use the same reference ranges for pregnant women as for the general population. Therefore, we suggest new reference limits for thromboelastography in pregnant women.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21543108     DOI: 10.1016/j.thromres.2011.04.007

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  8 in total

1.  Reference values for kaolin-activated thromboelastography in volunteers of Anhui Province in China.

Authors:  Jun-Bo Sun; Mao-Hong Bian; Tao Zhong; Ying-Yu Lu; Bang-Qiang Zhu; Hui-Qin Wen; Hai-Liang Hu
Journal:  J Clin Lab Anal       Date:  2017-01-30       Impact factor: 2.352

Review 2.  Recent Advances in the Management of Major Postpartum Haemorrhage - A Review.

Authors:  P Reddi Rani; Jasmina Begum
Journal:  J Clin Diagn Res       Date:  2017-02-01

Review 3.  Risk stratification for pregnancy-associated venous thromboembolism: Potential role for global coagulation assays.

Authors:  David O'Keefe; Hui Yin Lim; Lisa Hui; Prahlad Ho
Journal:  Obstet Med       Date:  2021-08-05

4.  Thromboelastography guiding decision-making for neuraxial labour analgesia in a patient with thrombocytopenia due to chronic portal hypertension.

Authors:  M J Wong; A Karuppiah; J H Galey; E Villamater; B S Kodali; S Bharadwaj
Journal:  Anaesth Rep       Date:  2021-04-07

5.  Time impact on non-activated and kaolin-activated blood samples in thromboelastography.

Authors:  Miroslav Durila; Pavel Lukáš; Jiří Bronský; Karel Cvachovec
Journal:  BMC Anesthesiol       Date:  2015-04-15       Impact factor: 2.217

6.  Establishment of thromboelastography reference intervals by indirect method and relevant factor analyses.

Authors:  Daye Cheng; Xiaoying Li; Shuo Zhao; Yiwen Hao
Journal:  J Clin Lab Anal       Date:  2020-01-31       Impact factor: 2.352

Review 7.  Haemostatic monitoring during postpartum haemorrhage and implications for management.

Authors:  C Solomon; R E Collis; P W Collins
Journal:  Br J Anaesth       Date:  2012-10-16       Impact factor: 9.166

8.  Establishment of the Normal Reference Range of Thrombelastogram among the Healthy Population and Pregnants in China.

Authors:  Rong Gui; Xueyuan Huang; Ming Zhou; Shujuan Ouyang; Yunfeng Fu; Hao Tang; Fengxia Liu; Rong Huang; Meng Gao; Hang Dong; Yongjun Wang
Journal:  Iran J Public Health       Date:  2019-05       Impact factor: 1.429

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.